Double antiplatelet therapy in patients with acute coronary syndrome

Double antiplatelet therapy in patients with acute coronary syndrome

The paper presents the evolution in the modern approaches towards antiplatelet therapy (aspirin, clopidogrel) in acute coronary syndrome, as well as the results of the studies on effectiveness and safety of such new antiaggregant medications as prasugrel and ticagrelor.

Bibliographic Details
Main Authors:	A. V. Rodionov, D. Kh. Aynetdinova, V. A. Sulimov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2011-10-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	острый коронарный синдром антиагреганты антитромбоцитарная терапия резистентность аспирин клопидогрел прасугрел тикагрелор
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1945

Similar Items

CLOPIDROGEL – HISTORIC AND MODERN BASIS OF ANTI-PLATELET THERAPY OF ACS
by: S. K. ZYRYANOV, et al.
Published: (2016-12-01)

INDIVIDUAL APPROACH TO PATIENTS WITH INDICATION FOR ANTIPLATELET THERAPY. WHAT TO RELY ON IN CHOOSING THE THERAPY?
by: N. V. LOMAKIN, et al.
Published: (2017-12-01)

SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
by: A. D. Erlikh
Published: (2017-05-01)

EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
by: Roman M. Shakhnovich
Published: (2018-12-01)

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

PLACE OF TICAGRELOR IN THE NEW RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. D. Ehrlich
Published: (2015-12-01)

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
by: P. S. LAGUTA, et al.
Published: (2017-12-01)

ДВОЙНАЯ АНТИТРОМБОЦИТАРНАЯ ТЕРАПИЯ: НЕОБХОДИМОСТЬ ПРИВЕРЖЕННОСТИ К ЛЕЧЕНИЮ И ВОЗМОЖНОСТИ ЕЕ ПОВЫШЕНИЯ
Published: (2014-12-01)

Сравнительный экономический анализ клопидогрела и тикагрелора при остром коронарном синдроме
Published: (2018-06-01)

DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE
by: G. N. Guseva, et al.
Published: (2015-09-01)

Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Потребность и потребление антитромбоцитарных препаратов у постинфарктных больных в РФ
Published: (2018-06-01)

Regarding the choice of Р2У<sub>12</sub> platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use
by: I. S. Yavelov
Published: (2020-12-01)

Antiplatelet treatment and gastro-intestinal hemorrhage risk
by: D. V. Duplyakov
Published: (2005-08-01)

АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА: ЧТО МЫ ЗНАЕМ О ВОЗМОЖНОСТЯХ ИНДИВИДУАЛИЗАЦИИ
Published: (2016-12-01)

Experience with the use of combination antithrombotic therapy in a patient with acute coronary syndrome and underlying severe coronavirus infection
by: D. A. Kurenkov, et al.
Published: (2022-06-01)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022-06-01)

EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME
by: A. V. Rudakova, et al.
Published: (2015-09-01)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Антиагреганты при заболеваниях периферических артерий: доказательная база, международные рекомендации
Published: (2018-06-01)

RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
by: N. F. Puchinyan, et al.
Published: (2016-01-01)

РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST
Published: (2016-01-01)

The role of clopidogrel in the current treatment of acute coronary syndrome
by: I. S. Yavelov
Published: (2020-06-01)

Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction
by: I. S. Yavelo
Published: (2022-01-01)

Modern potential of thrombotic complication prevention among patients with acute coronary syndrome without ST segment elevation in real clinical practice (Part I)
by: T. M. Poponina, et al.
Published: (1970-01-01)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016-01-01)

TO THE QUESTION OF EFFICACY AND SAFETY OF FORTELYZIN® THERAPY ON ACUTE CORONARY SYNDROME: TWO CLINICAL CASES
by: D. S. Yunevich, et al.
Published: (2018-03-01)

Клопидогрель в клинической практике при реваскуляризации миокарда: от истоков к последним рекомендациям
by: И. Гражданкин, et al.
Published: (2022-03-01)

Antiplatelet drug resistance in patients with coronary heart disease
by: V. A. Sulimov, et al.
Published: (2012-12-01)

Anticoagulants and antiaggregants in the COVID-19 era
by: A. D. Erlikh
Published: (2021-07-01)

Antiaggregant influence on platelet aggregation in patients with acute coronary syndrome without ST segment elevation
by: T. M. Poponina, et al.
Published: (2006-10-01)

Клопидогрель и предотвращение тромботических осложнений атеросклероза: стоимость таблеток или эффективность затрат?
Published: (2018-06-01)

PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM
by: O. O. Shakhmatova, et al.
Published: (2018-05-01)

NEW ANTIPLATELET DRUGS (PART 1)
by: A. B. Sumarokov
Published: (2016-01-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

Thrombosis prevention in percutaneous coronary interventions
by: V. P. Lupanov, et al.
Published: (2009-08-01)

HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?
by: E. P. PANCHENKO
Published: (2017-12-01)

Prospective study one-year clinical outcomes of the Calypso coronary stent in patients presenting with acute coronary syndrome
by: В. Л. Воробьев, et al.
Published: (2017-04-01)